
Alto Neuroscience (ANRO) is back in focus after reporting third quarter and nine month results that showed a wider net loss and higher loss per share compared with the prior year period.
Investors have reacted to the latest results with a sharp move in Alto Neuroscience’s share price, which is now at $28.61 after a 7 day share price return of 26.04%, while the year to date share price return of 72.45% and 1 year total shareholder return of 113.51% point to strong but recently choppy momentum.
Scan how Alto Neuroscience fits alongside other high-potential biotechs by reviewing a curated 36 healthcare AI stocks that are also reacting to key clinical and earnings catalysts.
After a move like Alto Neuroscience just logged, the central question is whether most of the gain is already in the rear-view mirror or whether the current valuation still leaves meaningful upside on the table.
Alto Neuroscience now trades at a P/B ratio of 5.1x, and that figure sits alongside a last close of $28.61 that has already moved sharply in recent weeks.
P/B compares the market value of the equity to its net asset value on the balance sheet. For a clinical-stage biotech with no revenue and a loss of $84.238m, investors are essentially paying a multiple of the cash, intellectual property, and pipeline potential rather than current earnings power.
Against that backdrop, the 5.1x P/B tag carries mixed messages. The ratio is lower than the peer average of 11.4x, which suggests the market price for Alto Neuroscience is more restrained than for similar biopharma stocks. Yet it is still much higher than the broader US Pharmaceuticals industry average of 1.9x, which points to a richer valuation than more diversified drug developers.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Price-to-book of 5.1x (ABOUT RIGHT)
Still, Alto Neuroscience carries real risk if clinical trials disappoint or if continued net losses of $84.238m force earlier than expected capital raising.
Find out about the key risks to this Alto Neuroscience narrative.
Uncertain about whether Alto Neuroscience has more room to run or is already pricing in a lot of optimism? Move fast, review the numbers directly, and pressure test the downside by starting with the 4 important warning signs.
If Alto Neuroscience has your attention, do not stop here. Broaden your watchlist with fresh ideas that match your risk level and return goals.
Use the Simply Wall Street screener to find focused opportunities that fit different approaches and help you avoid relying on a single story.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com